MedTrace Logo

A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer

NCT01548534 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2015-07-29

No results posted yet for this study

Summary

The aim of this study is to increase, by DHA-induced chemosensitization, the activity of anticancer chemotherapy in patients with a metastatic advanced breast cancer, by a nutritional approach with marin-derived PolyUnsaturated Fatty Acids (PUFA).

Conditions

Interventions

DIETARY_SUPPLEMENT

Dietary supplementation with fish oil.

Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.

DIETARY_SUPPLEMENT

Dietary supplementation with vegetable oil

Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    collaborator OTHER

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Philippe Bougnoux, MD, PhD · University Hospital, Tours

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01548534 on ClinicalTrials.gov